Notably, the immunomodulatory drug lenalidomide, commonly used in the treatment of MM, has been reported to reduce MPO levels in mouse models of colitis, and potently reduce MDSC induction in the context of MM.60, 61. The gene discussed is MPO; the disease is colitis.